文献速递炎症性肠病消化内镜

英夫利西单抗或环孢素治疗有效的激素难治性急性重度溃疡性结肠炎患者的内镜下病变演变

Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-08-07

前瞻性队列纳入随机对照试验中激素难治性急性重度溃疡性结肠炎且第98天达无激素临床缓解的患者,于基线及第7、42、98天行乙状结肠镜并计算UCEIS。内镜缓解始于出血缓解,血管纹理至第98天半数未达;英夫利西单抗组第98天全局内镜缓解率高于环孢素组(73% vs 25%,P<.001)。

要点

  • 内镜缓解过程始于出血缓解,血管纹理恢复最慢。
  • 第98天英夫利西单抗组全局内镜缓解率73%,环孢素组25%。
  • 部分内镜缓解率在出血和溃疡/糜烂高于血管纹理。

核心结论

  • 在激素难治性急性重度溃疡性结肠炎且对二线药物治疗有效的患者中,内镜缓解过程始于出血缓解,至第98天血管纹理约半数患者未达缓解。
  • 英夫利西单抗在第98天的全局内镜缓解率高于环孢素。

研究设计与样本

  • 前瞻性队列研究,纳入因激素难治性急性重度溃疡性结肠炎入院并参与比较英夫利西单抗与环孢素的随机试验、第98天达无激素临床缓解的患者。
  • 共分析55例患者(英夫利西单抗29例,环孢素26例),于基线及第7、42、98天行乙状结肠镜,事后计算UCEIS及其子评分。

主要发现

  • 基线时49例(83%)UCEIS≥6。
  • 第7天部分内镜缓解率:出血20% vs 血管纹理4%(n=55,P=.004),出血20% vs 溃疡/糜烂5%(n=55,P=.04)。
  • 第42天部分内镜缓解率:出血63%、溃疡/糜烂65% vs 血管纹理33%(n=54,两者P<.001)。
  • 第98天部分内镜缓解率:出血78%、溃疡/糜烂92% vs 血管纹理56%(n=50,P=.007和P<.001)。
  • 第98天全局内镜缓解率:英夫利西单抗组73% vs 环孢素组25%(n=26和24,P<.001)。

关键数值与推荐

  • 全局内镜缓解定义为UCEIS为0,部分内镜缓解定义为任一UCEIS子评分为0。
  • UCEIS子评分包括血管纹理、出血和溃疡/糜烂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Few data on the evolution of endoscopic findings are available in patients with acute severe ulcerative colitis (ASUC). The aim of this study was to describe this evolution in a prospective cohort. METHODS: Patients admitted for a steroid-refractory ASUC and included in a randomized trial comparing infliximab and cyclosporine were eligible if they achieved steroid-free clinical remission at day 98. Flexible sigmoidoscopies were performed at baseline, days 7, 42 and 98. Ulcerative colitis endoscopic index of severity (UCEIS) and its sub-scores - vascular pattern, bleeding and ulceration/erosion - were post-hoc calculated. Global endoscopic remission was defined by a UCEIS of 0, and partial endoscopic remission by any UCEIS sub-score of 0. RESULTS: Among the 55 patients analyzed (29 infliximab and 26 cyclosporine), 49 (83%) had UCEIS ≥6 at baseline at baseline. Partial endoscopic remission rates were higher for bleeding than for vascular pattern and for ulcerations/erosions at day 7 (20% vs. 4% and 5% (n = 55); p = .004 and p=.04), for bleeding and ulceration/erosion than for vascular pattern at day 42 [63% and 65% vs. 33% (n=54); p<.001 for both] and at day 98 [78% and 92% vs. 56% (n = 50); p = .007 and p < .001]. Global endoscopic remission rates at day 98 were higher in patients treated with infliximab than with cyclosporine [73% vs. 25% (n = 26 and 24); p < .001]. CONCLUSION: In steroid-refractory ASUC patients responding to a second-line medical therapy, endoscopic remission process started with bleeding remission and was not achieved in half the patients at day 98 for vascular pattern. Infliximab provided a higher endoscopic remission rate than cyclosporine at day 98.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Laharie D, Bourreille A, Branche J, et al. Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clin Gastroenterol Hepatol. 2020. PMID: 32777552. doi:10.1016/j.cgh.2020.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。